Last reviewed · How we verify
Reglan
At a glance
| Generic name | Reglan |
|---|---|
| Also known as | Metoclopramide |
| Sponsor | Emory University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: TARDIVE DYSKINESIA • Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including Reglan, the risk of developing TD increases with duration of treatment and total cumulative dosage [see Warnings and Precautions ( 5.1 )] . • Reglan is contraindicated in patients with a history of TD. • Use Reglan for the shortest duration of treatment and periodically reassess the need for con
Common side effects
- Restlessness
- Drowsiness
- Fatigue
- Lassitude
- Nausea
- Dizziness
- Headache
- Nervousness
- Bowel disturbances (diarrhea)
- Insomnia
- Confusion
- Visual disturbances
Serious adverse events
- Tardive dyskinesia
- Neuroleptic malignant syndrome
- Acute dystonic reactions
- Drug-induced parkinsonism
- Akathisia
- Convulsive seizures
- Hallucinations
- Depression with suicidal ideation
- Serotonin syndrome
- Acute congestive heart failure
Key clinical trials
- Restoration of Hypoglycemia Awareness With Metoclopramide (PHASE2)
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- Granisetron Combined With Dexamethasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecystectomy (PHASE4)
- IV Injection of Metoclopramide With or Without Dexamethasone (EARLY_PHASE1)
- Antibiotics and Vaccine Immune Responses Study (PHASE4)
- Effect of Dexmedetomidine on the Quality of Recovery in Parturients Undergoing Elective Caesarean Sections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reglan CI brief — competitive landscape report
- Reglan updates RSS · CI watch RSS
- Emory University portfolio CI